Bavarian Nordic Receives Health Canada Approval for
Health Canada has approved Bavarian Nordic's VIMKUNYA vaccine for the prevention of chikungunya in individuals aged 12 and older. This marks the fifth global regulatory approval for the single-dose vaccine.
Why it matters
Expanding access to vaccines for mosquito-borne diseases is a significant public health development for travelers and residents in endemic regions.
COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Health Canada has approved VIMKUNYA ® (recombinant, adsorbed) for immunization to prevent disease caused by chikungunya virus infection for individuals 12 years of age and older.
The article is a standard corporate press release regarding regulatory approval.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in